Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 11/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078708 | 0.85 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2079309 | 0.82 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2078754 | 0.82 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2079310 | 0.82 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2077577 | 0.82 | DRD3 (0.74) | DRD3DRD2 | |
| SCHEMBL969955 | 0.81 | DRD3 (0.74) | DRD3DRD2 | |
| SCHEMBL2079059 | 0.81 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2077591 | 0.80 | DRD3 (0.67) | DRD3DRD2 | |
| SCHEMBL323406 | 0.80 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2080515 | 0.80 | DRD3 (1.00) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1572214-B1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| EP-1572214-B1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | PFIZER INC | 2009-10-29 | — | — | US | disclosed |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | PFIZER INC | 2009-10-29 | — | — | US | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20060235016-A1 | Morpholine Dopamine Agonists | PFIZER INC | 2006-10-19 | — | — | US | disclosed |
| US-20060052435-A1 | Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction | VAN DER GRAAF PIETER H | 2006-03-09 | — | — | US | disclosed |
| EP-1572214-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| US-20040259874-A1 | Morpholine dopamine agonists | PFIZER INC. | 2004-12-23 | — | — | US | disclosed |
| EP-1463508-A1 | SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004052372-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003051370-A1 | SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051370-A1 | SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235016-A1 | Morpholine Dopamine Agonists | DBH, OPRM1, ADRA2B | DRD3 19/4885KDM4E 3956/4885USP2 3233/4885 |
| US-20040259874-A1 | Morpholine dopamine agonists | DBH, OPRM1, OPRD1 | DRD3 35/4885KDM4E 4218/4885USP2 2563/4885 |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | DBH, OPRM1, CHRM1 | DRD3 19/4885KDM4E 3890/4885USP2 3086/4885 |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | OPRL1, OPRD1, OPRK1 | DRD3 26/4885KDM4E 3456/4885USP2 4414/4885 |
| US-20060052435-A1 | Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction | DRD3, ADRB3, DRD2 | DRD3 1/4885KDM4E 4333/4885USP2 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.